Efektywność 10-walentnej szczepionki przeciwpneumokokowej skoniugowananej z białkiem D z nietypowalnej pałeczki hemofilnej (PHiD-CV)

The licensed in 2000 y. 7-valent pneumococcal conjugate vaccine (PCV7) has been evidenced to be highly efficient against invasive pneumococcal disease (IPD) (>95%) and also effective in reducing the incidence of acute otitis media (AOM) and community acquired pneumonia. The new, initially 11-walent, and later 10-walent pneumococcal vaccine uses protein D from non-typable Haemophilus influenzae (NtHi) not only as a protein carrier to stimulate recruitment of T lymphocytes and to fix and prolong immunogenicity against Streptococcus pneumonia, but as a separate antigen in order to induce immunity against NtHi. After three years of application of this vaccine and proving the efficacy in two controlled, randomized studies (POET and COMPAS) the significant effectiveness in reducing incidence of IPD in Quebeck Canada, in Finland (FinIP) and in subsequent monitoring study IPD, and also in Brazil where PHiD-CV was introduced to the National Immunization Programme (NIP).